Skip to content

Dipole Density Mapping of Typical Atrial Flutter

Dipole Density Right Atrial Mapping and Assessment of Therapy In Cavotricuspid Isthmus Flutter

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01914497
Acronym
DDRAMATIC
Enrollment
3
Registered
2013-08-02
Start date
2014-10-31
Completion date
2014-11-30
Last updated
2017-12-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Flutter

Brief summary

Study to determine the feasibility of the Acutus Medical System in obtaining data to create Dipole Density Maps of electrical activation in the right atrium in patients with typical atrial flutter.

Interventions

Sponsors

Acutus Medical
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

1. Be aged 18 to 75 years 2. Be scheduled for ablation of typical atrial flutter (cavotricuspid isthmus dependent) 3. Be able and willing to give informed consent

Exclusion criteria

1. Have any of the following: 1.1 Patients with implanted prosthetic, artificial, or repaired cardiac valves in the chamber being mapped. 1.2 Patients with permanent pacemaker or ICD leads in the chamber being mapped. 1.3Patients with hypercoagulopathy or an inability to tolerate anticoagulation therapy during an electrophysiology procedure. 2. Require treatment in the left atrium and/or a require a transseptal puncture to access the left atrium during the index procedure 3. Have had a myocardial infarction within the prior two months 4. Have had cardiac surgery within the prior three months 5. Have an intracardiac thrombus 6. Have clinically significant tricuspid valve regurgitation or stenosis 7. Have had any cerebral ischemic event (including transient ischemic attacks) in the prior six months 8. Be pregnant or nursing 9. Be currently enrolled in any other clinical investigation

Design outcomes

Primary

MeasureTime frame
Incidence of device-and procedure-related adverse events7 days
The number of patients in which offline construction of pre- and post-treatment activation maps can be completed7 days

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026